2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2541

Improving Adherence with Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the Traction Trial

Research Methodology Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 2223

Improving Clinical Decisions for Rheumatoid Arthritis Management Using Online Medical Simulations

Education Poster II

9:00AM-11:00AM: Abstract Number: 2219

Improving Outcomes with a Multimedia Patient Education Tool in Patients with Osteoporosis after 6 Months. a Randomized Controlled Trial

Education Poster II

9:00AM-11:00AM: Abstract Number: 2199

in Vivo Ubiquinol Supplementation Reduces the Pro-Atherothrombotic Status in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial

Antiphospholipid Syndrome: Clinical

9:00AM-11:00AM: Abstract Number: 2259

Incidence of Obesity, Diabetes and High Blood Pressure Associated with Arthritis: Analysis of the Canadian Longitudinal National Population Health Survey

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2821

Increased CD4 T Cell GM-CSF Production in Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II

9:00AM-11:00AM: Abstract Number: 3056

Increased Circulating Th17 Cells, Serum IL-17 and Serum IL-23 in Takayasu’s Arteritis

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2535

Increased Direct Healthcare Costs in SLE Pregnancies

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2809

Increased Frequencies of IL-23R Positive T Cells and IL-22 and IL-17 Producing MAIT Cells in the Peripheral Blood of Patients with Ankylosing Spondylitis: Preliminary Results.

Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 2715

Increased Frequency of Dysfunctional Hematopoietic Stem and Progenitor Cell Subpopulations in Treatment Naïve Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2798

Increased Frequency of the PTPN22W* Variant in Primary Sjögren’s Syndrome-Association with Low Type I IFN Scores in Peripheral Blood

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 3003

Increased Heparanase Expression in Keratinocytes Promotes Dermal Fibrosis in Scleroderma

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 3030

Increased Localization of Spleen Tyrosine Kinase (Syk) in Lipid Rafts of in Vitro TCR/CD3-CD28 Activated Lupus T Cells

T cell Biology and Targets in Autoimmune Disease Poster II

9:00AM-11:00AM: Abstract Number: 2582

Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2471

Increased Muscle Interferon-Gamma Expression Levels in Juvenile Dermatomyositis

Pediatric Rheumatology - Pathogenesis and Genetics Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].